

## Special Issue

# Modern Radiation Oncology: Predictions, Prognosis and Survivorship

### Message from the Guest Editors

Modern radiation oncology is rapidly evolving, bringing together technological innovation, biological insight, and patient-centered care. This Special Issue, “Modern Radiation Oncology: Predictions, Prognosis and Survival”, welcomes contributions that advance predictive modeling, refine prognostic assessment, and ultimately improve survival outcomes across cancer sites. Submissions addressing radiomics, artificial intelligence, and molecular markers are particularly encouraged, as are studies focused on long-term survivorship, late effects, quality of life, and supportive care in patients treated with radiotherapy. Together, these works aim to shape a more precise, holistic, and sustainable future for radiation-treated cancer survivors. Prof. Dr. Victor H. F. Lee

---

### Guest Editors

Prof. Dr. Victor H. F. Lee

Department of Clinical Oncology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

Dr. Shing Yau Tam

School of Medical and Health Sciences, Tung Wah College, Hong Kong, China

---

### Deadline for manuscript submissions

30 June 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/265741](https://mdpi.com/si/265741)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)